ISPOR - Are biomarkers a big market access bonus? us and eu5 payer perspectives and prescribing patterns for key targeted non-small-cell lung cancer agents

Full Text

Are biomarkers a big market access bonus? us and eu5 payer perspectives and prescribing patterns for key targeted non-small-cell lung cancer agents

Abstract

Authors

J. Cox D. Roberts D. Gheorghe R. Moore

Back to Volume 18, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now